Vertaling van "disease in patients with end-of-dose " (Frans → Nederlands) :

Treatment of idiopathic Parkinson’s disease (PD) in patients with end-of-dose fluctuations
idiopathic Parkinson’s disease (PD) in patients with end-of-dose fluctuations

Treatment of hyperparathyroidism in patients with end-stage renal disease on haemodialysis and of hypercalcaemia in patients with parathyroid carcinoma
Treatment of hyperparathyroidism in patients with end-stage renal disease on haemodialysis and of hypercalcaemia in patients with parathyroid carcinoma

Source Statement ACA Not included ACP Not included ASA Selected patients : Agreement : 90 % of consultants, 92 % ASA Members To consider : smoking, recent infection, COPD, and cardiac disease ICSI Selected patients with signs or symptoms suggesting new or unstable cardiopulmonary disease INAHTA Chest X-ray abnormality correspond more closely with ASA status than with age (McCleane) i The results of between 0% and 2.1% of chest X-rays leads to a change in management There is no published evidence that routine preoperative chest X-rays decrease perioperative risks ii . NICE Minor surgery: ASA I : not indicated ASA II : consider > 40 y if respiratory or CV disease ASA III : consider if respiratory or CV disease Intermediate surgery: ASA I : not indicated ASA II : consider if respiratory or CV disease (renal > 60y) ASA III : consider if respiratory, CV or renal disease Major surgery: ASA I : consider > 60 ASA II : consider if respiratory, CV or renal disease ASA III : consider if respiratory, CV or renal disease
Source Statement ACA Not included ACP Not included ASA Selected patients : Agreement : 90 % of consultants, 92 % ASA Members To consider : smoking, recent infection, COPD, and cardiac disease ICSI Selected patients with signs or symptoms suggesting new or unstable cardiopulmonary disease INAHTA Chest X-ray abnormality correspond more closely with ASA status than with age (McCleane) i The results of between 0% and 2.1% of chest X-rays leads to a change in management There is no published evidence that routine preoperative chest X-rays decrease

Décompensation hépatique chez les patients ayant une hépatite C chronique : les patients ayant un taux d’albumine bas (≤ 35 g/l) ou avec un score MELD (« Model for End Stage Liver Disease ») ≥ 10 à l’initiation doivent être surveillés.
Leverdecompensatie bij patiënten met chronische hepatitis C: controleer patiënten met lage albuminewaarden (≤ 35 g/l) of met ‘Model for End Stage Liver Disease’ (MELD) score ≥ 10 in de uitgangswaarde.

Il y a un risque accru d’événements indésirables, incluant une décompensation hépatique et des événements thrombo-emboliques potentiellement d’issue fatale, chez les patients thrombopéniques infectés par le VHC avec une maladie hépatique chronique avancée, définie par un taux bas d’albumine ≤ 35 g/l ou un score « MELD » (« Model for End Stage Liver Disease » - score du modèle pour la maladie hépatique au stade terminal) ≥ 10, lorsqu’ils sont traités par eltrombopag en association avec un traitement à base d’interféron.
Er is een verhoogd risico op bijwerkingen, waaronder mogelijk fatale leverdecompensatie en tromboembolische voorvallen, bij trombocytopene HCV-patiënten met een gevorderde chronische leverziekte, gedefinieerd door lage albuminewaarden van ≤ 35 g/l of MELD score ≥ 10, als zij worden behandeld met eltrombopag in combinatie met een behandeling op basis van interferon.

Les patients thrombopéniques ayant une infection chronique par le VHC avec un taux d'albumine bas (≤ 35 g/l) ou avec un score « Model for End Stage Liver Disease » (« MELD ») ≥ 10 à l’initiation avaient un risque plus élevé de décompensation hépatique lors d'un traitement par eltrombopag/interféron/ribavirine.
Trombocytopene patiënten met chronische HCV met lage albuminewaarden (≤ 35 g/l) of ‘Model for End-Stage Liver Disease’ (MELD) score ≥ 10 bij het begin van de behandeling, hadden een hoger risico op leverdecompensatie als ze werden behandeld met eltrombopag/interferon/ribavirin.

17. Nelson JC, Kennedy JS, Pollock BG, Laghrissi-Thode F, Narayan M, Nobler MS et al. Treatment of major depression with Nortriptyline and paroxetine in patients with ischemic heart disease.
17. Nelson JC, Kennedy JS, Pollock BG, Laghrissi-Thode F, Narayan M, Nobler MS et al. Treatment of major depression with nortriptyline and paroxetine in patients with ischemic heart disease.

randomized trials.1 Effective strategies for the secondary prevention of stroke include treatment of hypertension and hyperlipidemia, antithrombotic therapy for patients with atrial fibrillation, and antiplatelet therapy (Evidence level 1). 1 Statins are effective in the prevention of stroke, although evidence remains limited to heart disease patients (Evidence level 1). 2, 3
treatment of hypertension and hyperlipidemia, antithrombotic therapy for patients with atrial fibrillation, and antiplatelet therapy (Evidence level 1).1 Statins are effective in the prevention of stroke, although evidence remains limited to heart disease patients (Evidence level 1).2, 3

36. McKevitt FM, Macdonald S, Venables GS, Cleveland TJ, Gaines PA. Complications following carotid angioplasty and carotid stenting in patients with symptomatic carotid artery disease.
following carotid angioplasty and carotid stenting in patients with symptomatic carotid artery disease.

18. Roose SP, Laghrissi-Thode F, Kennedy JS, Nelson JC, Bigger JT, Jr., Pollock BG et al. Comparison of paroxetine and Nortriptyline in depressed patients with ischemic heart disease.
18. Roose SP, Laghrissi-Thode F, Kennedy JS, Nelson JC, Bigger JT, Jr., Pollock BG et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease.